[Federal Register Volume 71, Number 246 (Friday, December 22, 2006)]
[Notices]
[Pages 77038-77039]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-21905]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Method of Treating or 
Preventing Cancer Using Radiosensitizing Agents

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR Part 404.7(a)(1)(i), that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive patent license to practice the invention embodied in U.S. 
Provisional Patent Application No. 60/718,172, filed September 16, 
2005, entitled ``Method of Treating or Preventing Cancer Using Pyridine 
Carboxaldehyde Pyridine Thiosemicarbazone Radiosensitizing Agents'' [E-
319-2005/0-US-01; E-319-2005/0-PCT-02], to Vion Pharmaceuticals, Inc., 
having a place of business in New Haven, Connecticut. The patent rights 
in these inventions have been assigned to the United States of America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to the use of the Triapine as a 
radiosensitizer as claimed in the licensed patent rights for the 
treatment of cancer and other tumors.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
February 20, 2007 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Adaku Madu, J.D., Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 435-5560; Facsimile: (301) 402-0220; E-mail: 
[email protected].

SUPPLEMENTARY INFORMATION: This technology relates to using 2-
carboxyaldehyde pyridine thiosemicarbazone compounds or prodrugs 
thereof, specifically 3-amino-2-carboxyaldehyde pyridine 
thiosemicarbazone (Triapine) or 4-methyl-3-amino-2-carbozyaldehyde 
pyridine thiosemicarbazone, as radiosensitizing agents prior to 
administering ionizing radiation.

[[Page 77039]]

    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 
404.7. The prospective exclusive license may be granted unless within 
sixty (60) days from the date of this published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR Part 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: December 13, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
 [FR Doc. E6-21905 Filed 12-21-06; 8:45 am]
BILLING CODE 4140-01-P